Boehringer Ingelheim partners with GNA Biosolutions Boehringer Ingelheim partners with GNA Biosolutions Boehringer Ingelheim partners with GNA Biosolutions to develop African swine fever diagnostic test.
RE-LY-trial-publication-10-year-anniversary RE-LY-trial-publication-10-year-anniversary Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Research-collaboration-Gubra-obesity-treatment Research-collaboration-Gubra-obesity-treatment Boehringer Ingelheim and Gubra enter collaboration to identify and validate targets and innovative peptides for the treatment of obesity.
CHMP_opinion_Nintedanib_SSc-ILD CHMP_opinion_Nintedanib_SSc-ILD Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
collaboration-LIBD collaboration-LIBD Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
emperor-reduced-chmp-positive-opinion emperor-reduced-chmp-positive-opinion CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
Research ruminant animal health well-being Research ruminant animal health well-being Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research
Partnership for first-in-class cancer and CRM treatments Partnership for first-in-class cancer and CRM treatments Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
Co-creation with Communities Co-creation with Communities Making More Health has launched co-creation projects in Asia, Africa, Europe and other localities around the world with top social entrepreneurs.
TwistPak Mixing platform for swine vaccines TwistPak Mixing platform for swine vaccines TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds
Boosting performance with an inclusive performance culture Boosting performance with an inclusive performance culture Boosting performance of organizations with an inclusive performance culture
The GPP Forum The GPP Forum The generalized pustular psoriasis (GPP) Forum - a multistakeholder event collaborating for a new vision for people living with GPP
Over 100 billion birds vaccinated with VAXXITEK Over 100 billion birds vaccinated with VAXXITEK Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.
GastroGard the first imported equine drug in China GastroGard the first imported equine drug in China GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.
Cystic Fibrosis Genetherapy Development Option Excercise Cystic Fibrosis Genetherapy Development Option Excercise Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
Questions and Answers Questions and Answers Answers to common questions from both patients and health care professionals regarding Compassionate Use of experimental medications.
Partnership Boehringer Ingelheim Lifebit health data Partnership Boehringer Ingelheim Lifebit health data Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
preserved-heart-failure-treatment-approval-europe preserved-heart-failure-treatment-approval-europe preserved-heart-failure-treatment-approval-europe
FDA approves Jardiance treatment chronic kidney disease FDA approves Jardiance treatment chronic kidney disease U.S. FDA approves Jardiance® for treatment of adults with chronic kidney disease
Boehringer biopharmaceuticals China receives approval supply EU and US Boehringer biopharmaceuticals China receives approval supply EU and US Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
SPEVIGO CHMP positive opinion new indications SPEVIGO CHMP positive opinion new indications CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
Breakthrough Designation granted in US and China Breakthrough Designation granted in US and China SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares
New partnership to develop schizophrenia treatments New partnership to develop schizophrenia treatments Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments
Exploring innovation in interstitial lung disease (ILD) Exploring innovation in interstitial lung disease (ILD) Interstitial lung disease (ILD) describes a group of over 200 lung disorders characterized by inflammation and scarring of the interstitium of the lungs.